Walvax Biotechnology Co., Ltd. (300142.SZ)
CNY 10.47
(4.7%)
CNY 10.47
(4.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.43 Billion CNY | -24.1% |
| 2022 | 4.47 Billion CNY | 45.9% |
| 2021 | 3.06 Billion CNY | 20.84% |
| 2020 | 2.53 Billion CNY | 183.99% |
| 2019 | 894.12 Million CNY | 26.52% |
| 2018 | 706.7 Million CNY | 56.03% |
| 2017 | 452.92 Million CNY | 45.97% |
| 2016 | 310.28 Million CNY | -28.03% |
| 2015 | 431.12 Million CNY | 38.15% |
| 2014 | 312.06 Million CNY | -25.96% |
| 2013 | 421.46 Million CNY | -11.02% |
| 2012 | 473.64 Million CNY | 9.66% |
| 2011 | 431.91 Million CNY | 32.46% |
| 2010 | 326.07 Million CNY | 57.89% |
| 2009 | 206.51 Million CNY | 42.27% |
| 2008 | 145.16 Million CNY | 119.58% |
| 2007 | 66.1 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 622.3 Million CNY | 29.09% |
| 2024 Q3 | 554.1 Million CNY | -10.96% |
| 2024 Q1 | 482.06 Million CNY | -38.08% |
| 2023 Q2 | 1.18 Billion CNY | 67.51% |
| 2023 Q1 | 708.42 Million CNY | -41.22% |
| 2023 Q3 | 811.67 Million CNY | -31.6% |
| 2023 Q4 | 778.52 Million CNY | -4.08% |
| 2023 FY | 3.39 Billion CNY | -24.1% |
| 2022 FY | 4.47 Billion CNY | 45.9% |
| 2022 Q1 | 579.93 Million CNY | -52.04% |
| 2022 Q3 | 1.21 Billion CNY | -17.53% |
| 2022 Q2 | 1.47 Billion CNY | 154.39% |
| 2022 Q4 | 1.2 Billion CNY | -0.95% |
| 2021 Q4 | 1.2 Billion CNY | 78.99% |
| 2021 Q1 | 379.07 Million CNY | -68.07% |
| 2021 Q2 | 804.51 Million CNY | 112.23% |
| 2021 Q3 | 675.6 Million CNY | -16.02% |
| 2021 FY | 3.06 Billion CNY | 20.84% |
| 2020 Q1 | 73.14 Million CNY | -71.73% |
| 2020 Q2 | 380.73 Million CNY | 420.52% |
| 2020 FY | 2.53 Billion CNY | 183.99% |
| 2020 Q3 | 898.05 Million CNY | 135.88% |
| 2020 Q4 | 1.18 Billion CNY | 32.21% |
| 2019 Q2 | 260.28 Million CNY | 94.11% |
| 2019 FY | 894.12 Million CNY | 26.52% |
| 2019 Q1 | 134.08 Million CNY | -45.68% |
| 2019 Q3 | 240.97 Million CNY | -7.42% |
| 2019 Q4 | 258.77 Million CNY | 7.39% |
| 2018 Q1 | 92.05 Million CNY | -46.8% |
| 2018 FY | 706.7 Million CNY | 56.03% |
| 2018 Q3 | 160.03 Million CNY | -22.97% |
| 2018 Q4 | 246.84 Million CNY | 54.24% |
| 2018 Q2 | 207.76 Million CNY | 125.7% |
| 2017 Q3 | 120.73 Million CNY | 8.74% |
| 2017 FY | 452.92 Million CNY | 45.97% |
| 2017 Q1 | 48.11 Million CNY | -63.42% |
| 2017 Q2 | 111.02 Million CNY | 130.75% |
| 2017 Q4 | 173.04 Million CNY | 43.33% |
| 2016 Q3 | 62.41 Million CNY | 106.82% |
| 2016 FY | 310.28 Million CNY | -28.03% |
| 2016 Q1 | 86.14 Million CNY | -27.96% |
| 2016 Q4 | 131.54 Million CNY | 110.76% |
| 2016 Q2 | 30.17 Million CNY | -64.97% |
| 2015 Q2 | 115.04 Million CNY | 64.12% |
| 2015 FY | 431.12 Million CNY | 38.15% |
| 2015 Q4 | 119.57 Million CNY | -5.4% |
| 2015 Q3 | 126.4 Million CNY | 9.88% |
| 2015 Q1 | 70.09 Million CNY | 31.78% |
| 2014 Q1 | 84.95 Million CNY | -45.71% |
| 2014 Q2 | 106.69 Million CNY | 25.58% |
| 2014 Q3 | 67.22 Million CNY | -36.99% |
| 2014 Q4 | 53.19 Million CNY | -20.88% |
| 2014 FY | 312.06 Million CNY | -25.96% |
| 2013 Q1 | 80.33 Million CNY | -50.53% |
| 2013 Q2 | 117.79 Million CNY | 46.63% |
| 2013 Q3 | 66.83 Million CNY | -43.26% |
| 2013 Q4 | 156.49 Million CNY | 134.15% |
| 2013 FY | 421.46 Million CNY | -11.02% |
| 2012 Q2 | 152.67 Million CNY | 205.57% |
| 2012 Q1 | 49.96 Million CNY | -69.39% |
| 2012 FY | 473.64 Million CNY | 9.66% |
| 2012 Q4 | 162.37 Million CNY | 49.49% |
| 2012 Q3 | 108.62 Million CNY | -28.85% |
| 2011 Q3 | 103.99 Million CNY | -13.52% |
| 2011 Q4 | 163.2 Million CNY | 56.94% |
| 2011 Q1 | 44.46 Million CNY | -63.6% |
| 2011 FY | 431.91 Million CNY | 32.46% |
| 2011 Q2 | 120.25 Million CNY | 170.43% |
| 2010 Q2 | 84.26 Million CNY | 162.68% |
| 2010 FY | 326.07 Million CNY | 57.89% |
| 2010 Q4 | 122.15 Million CNY | 39.49% |
| 2010 Q3 | 87.57 Million CNY | 3.92% |
| 2010 Q1 | 32.07 Million CNY | 0.0% |
| 2009 FY | 206.51 Million CNY | 42.27% |
| 2008 FY | 145.16 Million CNY | 119.58% |
| 2007 FY | 66.1 Million CNY | 0.0% |